The authors describe a case of thrombocythaemia, with subsequent leukaemic transformation. Cytochemical and immunocytochemical investigations indicated a trilineage involvement of the myeloid series, compatible with a leukaemic transformation at the level of the colony-forming unit granulocytes, erythrocytes, macrophages, megakaryocytes. No cytogenetic abnormalities were observed. The criteria which have been proposed to differentiate essential thrombocythaemia from pre-fibrotic thrombocythaemia, as an early phase of idiopathic myelofibrosis, are discussed. The differentiation is not only of academic interest but has relevant practical implications, since survival in the two conditions is significantly different. The possible significance of an accompanying monoclonal gammopathy is discussed.

1.
Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, Bauters: Clinical course of essential thrombocythemia in 147 cases. Cancer 1990;66:549–556.
2.
Raman SBK, Mahmood A, Van Slyck EJ, Saeed SM: Essential thrombocythaemia with transition into acute leukaemia. Ann N Y Acad Sci 1981;370:145–153.
3.
Sedlacek SM, Curtis JL, Weintraub J, Levin J: Essential thrombocythemia and leukemic transformation. Medicine 1986;65:353–364.
4.
Geller SA, Shapiro E: Acute leukemia is a natural sequel to primary thrombocythemia. Am J Clin Pathol 1982;77:353–356.
5.
Murphy PT, Sivakumaran M, van Rhee F, Watmore AE, Mitchell VE: Acute lymphoblastic transformation of essential thrombocythaemia. Br J Haematol 1995;89:921–922.
6.
O’Hea AM, Erber W, O’Connor NTJ, Bunch C: Acute transformation of essential thrombocythaemia: Report of two cases. J Clin Pathol 1986;39:1296–1298.
7.
Woronzoff-Dashkoff KK, Litz CE: Acute lymphoblastic leukemia in a case of essential thrombocythemia. Am J Clin Pathol 1996;106:206–208.
8.
Higuchi T, Okada S, Mori H, Omine M, Terada H: Leukemic transformation of polycythemia vera and essential thrombocythemia possibly associated with an alkylating agent. Cancer 1995;75:471–477.
9.
Patiño-Sarcinelli F, Knecht H, Pechet L, Pihan G, Savas L, Snyder LM: Leukemia with megakaryocytic differentiation following essential thrombocythemia and myelofibrosis. Acta Haematol 1996;95:122–128.
10.
Thiele J, Kvasnicka HM, Diehl V, Fischer R, Michiels JJ: Clinicopathological diagnosis and differential criteria of thrombocythaemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies. Leuk Lymphoma 1999;33:207–218.
11.
Rozman C, Giralt M, Feliu R, Rubio D, Cortes MT: Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991;67:2658–2663.
12.
Iland HJ, Laszlo J, Case DC, Murphy S, Reichert TA, Tso CY, Wasserman LR: Differentiation between essential thrombocythemia and polycythemia vera with marked thrombocytosis. Am J Hematol 1987;25:191–201.
13.
Murphy S, Iland H, Rosenthal D, Laszlo J: Essential thrombocythemia: An interim report from the Polycythemia Vera Study Group. Semin Hematol 1986;23:177–182.
14.
Michiels JJ: Diagnostic criteria of the myeloproliferative disorders (MPD): Essential thrombocythemia, polycythemia vera and chronic megakaryocytic granulocytic metaplasia. Neth J Med 1997;51:57–64.
15.
Michiels JJ, Juvonen E: Proposal for revised diagnostic criteria of essential thrombocythemia and Polycythemia Vera Study Group. Semin Thromb Hemost 1997;23:339–347.
16.
Thiele J, Kvasnicka HM, Werden C, Zankovich R, Diehl V, Fisher R: Idiopathic primary osteo-myelofibrosis: A clinico-pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact. Leuk Lymphoma 1996;22:303–317.
17.
Quaglino D, Hayhoe FGJ: Haematological Oncology – Clinical Practice. Edinburgh, Churchill Livingstone, 1992.
18.
Nagata T, Mugishima H, Yoden A, Yoshikawa K, Oguni T, Yamashiro K, Yamamori S, Harada K: A case of monoclonal gammopathy associated with acute myelomonocytic leukemia with eosinophilia suggested to be the result of lineage infidelity. Am J Hematol 2000;65:66–71.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.